Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24317329 | 0.94 | TSHR (0.48) | L3MBTL1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL27010244 | 0.94 | TSHR (0.53) | L3MBTL1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL27010315 | 0.93 | L3MBTL1 (0.51) | L3MBTL1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL26620363 | 0.87 | TSHR (0.52) | L3MBTL1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL24317829 | 0.87 | ALDH1A1 (0.57) | TSHRALDH1A1LMNASMN1; SMN2MAPK1 | |
| SCHEMBL27010377 | 0.87 | L3MBTL1 (0.47) | L3MBTL1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL26620352 | 0.85 | L3MBTL1 (0.50) | L3MBTL1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL27010379 | 0.85 | L3MBTL1 (0.48) | L3MBTL1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL24315792 | 0.85 | TSHR (0.57) | L3MBTL1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL27010243 | 0.84 | TSHR (0.52) | L3MBTL1TSHRALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | L3MBTL1 3664/4885TSHR 2445/4885ALDH1A1 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.